CoChat

Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Supratentorial diffuse low-grade gliomas present a slow macroscopic tumor growth that can be quantified through the measurement of their velocity of diametric expansion. We assessed whether spontaneous velocity of diametric expansion can predict long-term outcomes as a categorical variable and as a continuous predictor. METHODS: A total of 407 adult patients with newly diagnosed supratentorial diffuse low-grade gliomas in adults were studied. RESULTS: The mean spontaneous velocity of diametric expansion before first-line treatment was 5.8 ± 6.3 mm/year. During the follow-up (mean, 86.5 ± 59.4 months), 209 patients presented a malignant transformation, and 87 died. The malignant progression-free survival and the overall survival were significantly longer in cases of slow velocity of diametric expansion (median, 103 and 249 months, respectively) than in cases of fast velocity of diametric expansion (median, 35 and 91 months, respectively; P < .001). In multivariate analyses, spontaneous velocity of diametric expansion as a categorical variable (<4, ≥4 and <8, ≥8 and <12, ≥12 mm/year) was an independent prognostic factor for malignant progression-free survival (P < .001; hazard ratio, 3.87; 95% confidence interval [CI], 2.67-5.52) and for overall survival (P < .001; hazard ratio, 4.62; 95% CI, 2.58-7.97). Velocity of diametric expansion was also an independent prognostic factor for overall survival as a continuous predictor, showing a linear relationship between overall survival and spontaneous velocity of diametric expansion (hazard ratio, 1.09 per one unit increase; 95% CI, 1.06-1.12; P < .001). CONCLUSIONS: Independent of the molecular status, the spontaneous velocity of diametric expansion allows the identification of rapidly growing diffuse low-grade gliomas (at higher risk of worsened evolution) during the pretherapeutic period and without delaying treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nos331

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Reifenberger, 2007, Oligodendroglioma, 54
  2. von Deimling, 2007, Diffuse astrocytomas, 25

Cited by

See all 174

Metadata

Authors
Pallud, J., Blonski, M., Mandonnet, E., Audureau, E., Fontaine, D., Sanai, N., Bauchet, L., Peruzzi, P., Frénay, M., Colin, P., Guillevin, R., Bernier, V., Baron, M.-H., Guyotat, J., Duffau, H., Taillandier, L., & Capelle, L.
Affiliations
Barrow Neurological Institute (US)
Corresponding author
Pallud, Johan
Venue
Neuro-Oncology
Published
2013-02-07
Volume
15
Issue
5
Pages
595-606
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2160995760
Cited by
173
References
33
Citations by year
2026: 5 · 2025: 18 · 2024: 8 · 2023: 12 · 2022: 14 · 2021: 13 · 2020: 17 · 2019: 15 · 2018: 16 · 2017: 24 · 2016: 5 · 2015: 11 · 2014: 11 · 2013: 4
FWCI
5.08
Type
journal article
Language
en
Open access
Locations
  • Neuro-Oncology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
diffuse low-grade glioma, tumor growth rate, malignant transformation, prognostic factors, progression-free survival, overall survival, supratentorial glioma, adult glioma
MeSH terms
Adolescent, Adult, Aged, Brain Neoplasms, Female, Follow-Up Studies, Glioma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Survival Rate, Tumor Burden, Young Adult, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.